Add-on Therapy of EPA Reduces Oxidative Stress and Inhibits the Progression of Aortic Stiffness in Patients with Coronary Artery Disease and Statin Therapy: A Randomized Controlled Study

Akira Takaki; Seiji Umemoto; Kaoru Ono; Kouzaburo Seki; Tsutomu Ryoke; Akihisa Fujii; Tatsunori Itagaki; Masahiko Harada; Masakazu Tanaka; Takahito Yonezawa; Hiroshi Ogawa; Masunori Matsuzaki

doi:10.5551/jat.7260

Original Article

Add-on Therapy of EPA Reduces Oxidative Stress and Inhibits the Progression of Aortic Stiffness in Patients with Coronary Artery Disease and Statin Therapy: A Randomized Controlled Study

Akira Takaki, Seiji Umemoto, Kaoru Ono, Kouzaburo Seki, Tsutomu Ryoke, Akihisa Fujii, Tatsunori Itagaki, Masahiko Harada, Masakazu Tanaka, Takahito Yonezawa, Hiroshi Ogawa, Masunori Matsuzaki

Author information

Akira Takaki
Department of Cardiology, Tokuyama Central Hospital.
Takaki Medical Clinic.
Seiji Umemoto
Pharmaceutical Clinical Research Center, Yamaguchi University Hospital.
Kaoru Ono
Department of Cardiology, Shunan City Shinnanyou Hospital.
Ono Clinic.
Kouzaburo Seki
Department of Cardiology, Yamaguchi Rosai Hospital.
Tsutomu Ryoke
Department of Cardiology, Shimonoseki Kosei Hospital.
Ryoke Cardiology Clinic.
Akihisa Fujii
Department of Cardiology, Yamaguchi Rosai Hospital.
Mitsuyama Clinic.
Tatsunori Itagaki
Department of Cardiology, Hikari Municipal Yamato General Hospital.
Masahiko Harada
Department of Cardiology, Ube Industries Central Hospital.
Masakazu Tanaka
Department of Cardiology, Shuto General Hospital.
Ishihara Internal Medicine and Cardiology Hospital.
Takahito Yonezawa
Department of Cardiology, Souyou Hospital.
Hiroshi Ogawa
Department of Cardiology, Tokuyama Central Hospital.
Masunori Matsuzaki
Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine.

Keywords: Eicosapentaenoic acid, Oxidative stress, Arterial stiffness, Coronary artery disease

JOURNAL OPEN ACCESS

2011 Volume 18 Issue 10 Pages 857-866

DOI https://doi.org/10.5551/jat.7260

View "Advance Publication" version (June 23, 2011).

Details

Abstract

Aim: We examined the anti-oxidant mechanisms of combined therapy of eicosapentaenoic acid (EPA) plus statin on the progression of atherosclerosis.
Methods: Patients receiving statin therapy for dyslipidemia and with coronary artery disease (CAD) were assigned randomly in an open-label manner to the EPA (1,800 mg/day) -plus-statin group (n= 25; combined-therapy group) or to the statin-only group (n= 25), and followed for 48 weeks. At baseline and 48 weeks after enrollment, oxidative stress, brachial-ankle pulse wave velocity (baPWV) and stiffness parameter β-index of the carotid were measured.
Results: The lipid profile remained unchanged throughout the study. Although the median value of baPWV increased more in the statin-only group than in the combined-therapy group, this difference was not significant (p= 0.29); however, a decrease in baPWV was associated with combined-therapy treatment by multiple regression analysis adjusted for age and mean blood pressure (p= 0.04). In addition, the β-index of the carotid was lower in the combined-therapy group than in the statin-only group (p= 0.02). Furthermore, although the difference in the reduction of the urinary concentration of 8-isoprostane between the two groups did not reach statistical significance, this concentration was significantly lower in the combined-therapy group with higher baseline levels (≥ 183 pg/mL · Cr) of urinary 8-isoprostane (p= 0.004).
Conclusions: EPA may reduce oxidative stress and inhibit the progression of arterial stiffness more efficiently than statin-only therapy in patients with dyslipidemia and CAD.

Corresponding author

Register with J-STAGE for free!